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Abstract
Purpose—Early detection is essential for treatment plans before onset of metastatic disease. Our 
purpose was to demonstrate feasibility to detect and monitor estrogen receptor 1 (ESR1) gene 
mutations at the single circulating tumor cell (CTC) level in metastatic breast cancer (MBC).
Experimental Design—We used a CTC molecular characterization approach to investigate 
heterogeneity of 14 hot spot mutations in ESR1 and their correlation with endocrine resistance. 
Combining the CellSearch® and DEPArray™ technologies allowed recovery of 71 single CTCs 
and 12 WBC from 3 ER-positive MBC patients. 40 CTCs and 12 WBC were subjected to whole 
genome amplification by MALBAC and Sanger sequencing.
Results—Among 3 selected patients, 2 had an ESR1 mutation (Y537). One showed two different 
ESR1 variants in a single CTC and another showed loss of heterozygosity. All mutations were 
detected in matched cell-free DNA (cfDNA). Furthermore, one had 2 serial blood samples 
analyzed and showed changes in both cfDNA and CTCs with emergence of mutations in ESR1 
(Y537S and T570I), which has not been reported previously.
Conclusions—CTCs are easily accessible biomarkers to monitor and better personalize 
management of patients with previously demonstrated ER-MBC who are progressing on endocrine 
therapy. We showed that single CTC analysis can yield important information on clonal 
heterogeneity, and can be a source of discovery of novel and potential driver mutations. Finally, we 
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also validate a workflow for liquid biopsy that will facilitate early detection of ESR1 mutations, 
the emergence of endocrine resistance and the choice of further target therapy.
Keywords
ESR1 mutation; single circulating tumor cell; metastatic breast cancer; endocrine resistance; tumor 
heterogeneity
INTRODUCTION
Breast cancer (BC) is the most frequent cancer and the leading cause of cancer death among 
women. Despite advances in prevention, diagnosis and adjuvant treatment, about 30% of BC 
patients develop metastatic disease [1]. Recent advances suggest that the presence of 
different tumor cell clones play an important role in metastatic progression and resistance to 
chemotherapy [2]. According to the clonal theory of tumor evolution, cancer is an evolving 
process [3] and the selective pressure exerted by multiple lines of treatment may lead to 
selection of much more aggressive sub-clone populations or even those with an acquired 
drug resistance [4].
About 75% of breast cancers express the estrogen receptor (ER); and, acting on this 
signaling pathway is a key treatment strategy. The main endocrine therapeutic approaches 
are: 1) selective ER modulators (SERMs); 2) inhibitor of aromatase (AIs); and, 3) selective 
ER down-regulators (SERDs) [5]. However, in 20–25% of metastatic breast cancer (MBC) 
patients endocrine therapy failure has been reported after several lines of treatment and new 
targeted therapies have been approved to be combined with hormone therapy [6,7,8]. Several 
molecular mechanisms of resistance may be involved, including down-regulation and post-
translational modification of the ER encoded by the ESR1 gene [9]. Since ESR1 mutations 
are rare, occurring in only 1% of primary BC, their ability to confer endocrine resistance has 
been speculated for many years [10]. However, in metastatic tissues the incidence of such 
mutations is estimated at 20% [11]. In the last several years, 14 ESR1 point mutations have 
been reported, mainly localized in the ligand-binding domain (LBD) including 3-hot spot 
mutations in codons 380, 537 and 538. Functional study of these mutations showed an ER 
ligand-independent activity, highlighting their role in acquired endocrine resistance [12,13]. 
Therefore, genomic characterization of distant metastasis may provide clinically useful 
information for the selection of specific therapeutic treatments [14,15]. Even though genetic 
testing on repeated metastatic biopsies may not be representative of the whole tumor mass, 
and leads to an underestimation of tumor heterogeneity [16].
Liquid biopsy using either circulating tumor cells (CTCs) or cell-free tumor DNA (ctDNA) 
has become one of the most sensitive approaches to monitor tumor molecular evolution 
[17,18]. CTCs can be isolated non-invasively over time [19] and over the past decade, the 
prognostic value of CTCs has been shown in metastatic breast, colorectal and prostate 
cancer [20,21,22,23,24,25,26]. Significant advances in cancer diagnosis and in the 
evaluation of disease progression and treatment can be reached with single CTC analysis 
because of the improvements made in single cell genomics analysis [27]. Currently, there are 
few techniques available for single cell isolation, including micromanipulation, laser micro-
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dissection and high throughput fluorescence-activated cell sorting (FACS). These 
approaches have several disadvantages including inadequate detection sensitivity for CTC 
population, a required high number of cells as a starting population and are manual and 
laborious methods [28,29,30].
We decided to study the molecular features of CTCs in patients with hormone-receptor 
positive (HR+) MBC receiving endocrine therapy. We planned to validate a laboratory 
workflow for single CTC detection, isolation and molecular analysis by combining the 
sequential use of CellSearch® [20,21,22,23,24,25,26], DEPArray™ systems [31,32] and 
MALBAC techniques [33]. The purpose of this study was to investigate the incidence and 
heterogeneity of ER expression and to evaluate the detection of ESR1 mutations in 
individual CTCs. We also planned to compare our single CTC data with matched cfDNA.
MATERIALS AND METHODS
Patients and sample collection
Thirty MBCs patient were enrolled at the Department of Medical Oncology, Thomas 
Jefferson University in Philadelphia, between February and September 2015. Only patients 
with a primary ER-positive metastatic breast cancer were included. Clinical parameters 
included sex, age at surgery, differentiation grade, lymph node metastasis, distant metastasis, 
TNM stage and histology. Progesterone receptor (PR) and ER status of the primary tumor 
and of available metastases were recorded. All subjects gave informed consent and the study 
was approved by the Institutional Review Board. For each patient, 10 ml of blood was 
collected in two CellSave™ tubes (Veridex, LLC) for enrichment, enumeration and 
molecular characterization of CTCs using the FDA-approved CellSearch® System. All 
samples were taken at least 5 days after the last treatment. Matching primary tumor tissues 
were tested for presence of mutations in ER receptor before starting hormonal therapy.
Cell lines
Two human breast cancer cell lines (MCF-7 and FC-IBC-02), and a prostate cancer cell line 
(C4-2) were used to validate whole genome amplification experiments. MCF-7 cells were 
maintained in DMEM containing 10% (v/v) FBS, 100 units/ml penicillin and 100 mg/ml 
streptomycin. FC-IBC-02 primary cells were isolated from pleural effusion of IBC patients 
and cultured in Ham’s F12 with 10% (v/v) FBS, 5 ml Insulin and 100 µg/µl of 
hydrocortisone with antibiotic-antimicotic. C4-2 cell line was cultured in RPMI with 2.5–
10% (v/v) FBS as previously described [34] All cell lines were maintained in T-25 or T-75 
flasks using prescribed cell culture conditions [5% (v/v) CO2, 37 °C].
Quality control and experimental procedure validation
Single tumor cells were obtained from MCF-7 and FC-IBC-02 cell lines through 
micromanipulation and from C4-2 cell line by serial dilution. All collected cells were 
processed for MALBAC. Meanwhile, 30 pg of genomic DNA carrying the V600E mutation 
in the BRAF gene was used as MALBAC positive control for all WGA products. To validate 
the CellSearch® ability to capture CTC, 100 C4-2 cells were spiked into a healthy donor 
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blood sample. Captured C4-2 cells together with WBC from the healthy donor were loaded 
on the DepArray cartridge to achieve single cell isolation and capture.
DEPArray™ system is a semiautomated system that allows the isolation of rare fluorescently 
labelled cells. An electric field is generated on the surface of a silicon chip directly 
interfaced to a microfluidic chamber containing the cell suspension and an array of 
electrodes. Each electrode can be programmed to achieve a cage of dielectrophoresis, inside 
of which single CTC can be trapped and then analyzed individually.
Individual C4-2 and WBC cells were subsequently MALBAC amplified and screened for 7 
known mutations in the AR, CDH1, PIK3C3, NCOR2, ERBB2, CDK4 and ETV1 genes by 
Sanger sequencing. C4-2 and WBC genomic DNA from a healthy donor also were used to 
confirm the 7 variants by Sanger sequencing.
Enrichment, immune labeling and enumeration of CTCs
Standard CellSearch® protocol for CTCs enrichment and enumeration was employed 
according to the manufacturer’s instructions. Briefly, CTCs were enriched on the CellTracks 
Autoprep® using ferrofluid conjugated with EpCAM antibody. Cells were stained with 
fluorescently labeled monoclonal antibody for cytokeratin CK8-, CK18-, CK19-FITC as 
well as for leuckocyte common antigen CD45-APC and nuclear-stained with DAPI. 
Moreover, ER expression on MCF-7 cells and CTCs was assessed by staining the cells with 
a PE-conjugated anti-ER nuclear antibody.
Since the DEPArray™ system (Silicon Biosystem, San Diego, CA) provides the analysis of 
only 66% of the loaded volume, to optimize single CTC recovery rate, only patients 
exhibiting >20 CTCs (ER+ and ER-) were processed.
Single CTC isolation
Briefly, for each CellSearch enriched sample, 13 µl were loaded with 325 µl manipulation 
buffer (SB115, Silicon Biosiystem) into a A300K cartridge. Approximately 8.6 µl of the 
sample is de facto dielectrophoretically processed in which cells are individually trapped in 
cage. The cartridge is then scanned by an automated fluorescence microscope and cells 
detected by DAPI staining. Three different populations of cells were isolated: 1) ER+ CTCs, 
defined as ER-positive, CK-8, CK-18, CK-19 positive, CD45 negative; 2) ER- CTCs, 
defined as ER-negative, CK positive, CD45 negative; and, 3) WBCs, defined as CD45 
positive, ER- and CK negative. Each cell was collected individually, washed two times in 
PBS and stored at −80°C or immediately lysed in accordance with MALBAC protocol [35]. 
To minimize DNA contamination in the same isolation cage containing the individual cell, 
an aliquot of the elution buffer from the single cage was MALBAC-amplified and subjected 
to DNA Sanger sequencing. No mutation was detected on all elution buffer reactions. 
Moreover, for each sequencing run, a no template control also was tested.
Whole Genome Amplification
Cell lysis and genome amplification was performed using the MALBAC kit (Yikon 
Genomics YK001A/B version 1302.1, Jiangsu, China) [33], following manufacturer’s 
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instructions. A negative no template control (NTC), a blank control (SB115) and a 
MALBAC positive control were used for each MALBAC reaction. WGA products were then 
purified according to Agencourt AMPure XP bead kit (Beckman Coulter, Sharon Hill, PA) 
manufacturer’s protocol [36] and QC using Qubit® dsDNA High Sensitivity Assay kit 
(ThermoFisher, Waltham, MA). WGA products were run on 0.8% (v/v) agarose gel and 
checked for expected distribution in size (300 to 2000 bp).
Sanger sequencing
Sanger sequencing was performed to genotype all WGA products as well as 14 hot-spot 
mutations in the ESR1 gene found in MBC tissues and related controls on an AB 3730 
following manufacturer’s protocol. Detailed PCR conditions (Tm) and primer sequences are 
available in supplementary methods (Table 1 supplementary methods). Sequences were 
analyzed and genotyped by SeqScape v3.0 analysis software (ThermoFisher, Waltham, MA).
RESULTS
To investigate whether detection of ESR1 mutations in individual CTCs in MBC patients 
could be used as a tool to enable monitoring of the metastatic burden for clinical decision-
making, a 4-step protocol was implemented with the following workflow: 1) CTC 
enrichment; 2) Single cell isolation; 3) Whole genome amplification; 4) Sanger sequencing 
(Figure 1).
Patient and pathological features
A cohort of 30 metastatic breast cancer patients was characterized by a median age of 56 
years. 36.6% of the patients showed evidence of one single metastatic lesion while 64% 
showed more than one at the time of the first draw. Clinical and pathological features of 
primary and metastatic tumor tissues are summarized in Table 1. Among the total number of 
patients, 28 had histologically confirmed ER positivity even at metastatic sites. At the time 
of surgery, primary tumor tissues were investigated for presence of ER mutations and all 
harbored a wild-type genotype.
Enrichment, isolation and genome amplification of individual CTCs
Enrichment and enumeration of CTCs performed on CellSearch® involved a total of 50 
blood samples taken from the 30 patients enrolled. Number of CTCs based on ER 
expression (Figure 2) for each patient (ID) are shown in Table 2. Overall, the average of total 
CTCs enumerated was 80, with a maximum of 1375 cells. 22% of samples were negative 
(no CTCs) for presence of CTCs, defining a group of patients currently responsive to current 
treatment. The remaining 39 samples were divided into two groups depending on the 
established cut-off of 5 CTCs [37] used to identify patients with high risk of disease 
progression (12 samples <5 CTCs vs 27 samples ≥5 CTCs). Only 4 of the 50 samples 
analyzed showed a number of CTCs greater or equal to 20 and were processed on the 
DEPArray™. Seventy-one single CTCs and 12 white blood cells (WBCs) were retrieved. 
Forty of these CTCs and all the WBCs were subjected to WGA. The number of CTCs 
(subdivided in ER+ or ER-) isolated for each individual patient and the corresponding 
Paolillo et al. Page 5
Clin Cancer Res. Author manuscript; available in PMC 2018 October 15.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
number of selected cells for WGA are summarized in Table 3. Samples processed on 
DEPArray™ showed between 21% and 30% of CTCs recovered.
Pre-clinical validation of single cell genome amplification and analysis
Validation of single cell genome amplification was conducted on 30 individual single cells. 
DNA positive controls, after MALBAC amplification showed heterozygosity for the BRAF 
V600E (c.1860T>a) mutation (data not shown), as expected. No other BRAF mutations 
were found in all the wild-type single cells analyzed, demonstrating feasibility of the 
protocol.
Following spiking, enrichment and immune-labeling, 91 positive CTCs were detected by 
CellSearch®. 65% of these CTCs were identified on the DEPArray™ and finally 10 
individual cells were recovered and subjected to whole genome amplification. In addition, 
10 WBCs were recovered and subjected to WGA, as negative control. The sequences 
obtained from all the C4-2 cells (single or pooled) revealed all 7 carried known mutations 
(AR/T878A, CDH1/P94T, CDK4/P110L, ErbB2/E930D, ETV1/G207E, NCOR2/L167P, 
PIK3C3/F524C) (data not shown). Sequences obtained from the 10 WBCs from healthy 
donor’s buffy coat showed wild-type genotypes for all variants tested.
ESR1 mutational analysis in single CTCs
ESR1 mutation analysis was successfully performed on all single cells isolated. All 
mutations were located within the ligand-binding domain of the ESR1 gene in exons 4, 5, 6, 
7 and 8 (Figure 3). All 12 WBCs, showed a wild type genotype confirming the absence of 
mutations in the germ line. Overall, we found ESR1 mutations in a total of 8 CTCs 
belonging to 2 MBC patients. High levels of intra- and inter-tumor genetic heterogeneity in 
ER positive CTCs populations also was revealed. The remaining 32 CTCs analyzed showed 
a wild-type ESR1 genotype. For patient ID20, a total of 5 single CTCs were analyzed and all 
showed wild type phenotype. Patient ID19 exhibited a heterogeneous ESR1 genotype in 
their CTC populations. Among the ER+ CTCs population we detected 3 different genotypes: 
a) one single wild type CTC; b) 3 CTCs heterozygous for a single mutation (Y537S) in exon 
8 (Figure 3a); c) one single CTC homozygous for the same Y537S (LOH) (Figure 3b). 
Matching cfDNA was tested, confirming the Y537S mutation at 0.25% allele frequency. 
Patient ID10 was the only one who had 2 serial blood samples taken, 3 months apart. The 
first sample showed an ESR1 wild type genotype in all the 12 CTCs recovered. The second 
showed a wildtype genotype in all 8 ER- CTCs, and in 4 of the ER+ CTCs recovered. Three 
CTCs were heterozygous for the Y537S mutation, whereas the remaining ER+ CTC 
harbored 2 different mutations in exon 8. Other than the Y537S we found a new mutation, 
not reported until now, the T570I (Figure 3c). Also in this case data were compared with 
those obtained on matching cfDNA. No mutation was detected at the first draw, while 
Y537S was detected at the second sampling at a percentage of 0.18%.
Correlation between ESR1 mutation and patients’ treatment
Patient ID19 with the Y537S mutation had only one sampling for CTC enumeration and 
circulating free tumor DNA (cfDNA) analysis. The first diagnosis of inflammatory ductal 
breast cancer was made in 2010, and the patient opted for holistic remedies. In 2011 the 
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patient developed ascites and pleural effusions and started a chemotherapeutic treatment 
(Docetaxel-Cytoxan) for six months, followed by endocrine therapy with Aromasin. In 2014 
the patient was subjected to 6 cycles of Doxil and Faslodex, but in January 2015, a liver 
metastasis was found. This progression to metastatic disease during treatment indicated a 
failure in the therapeutic approach. The analysis of CTCs and cfDNA confirmed this 
suspicion, with the finding of the Y537S activating mutation.
Patient ID10 reported two mutations, the Y537S and the newly reported T570I. This case 
report shows how the monitoring of ESR1 mutations can be crucial to monitor and predict 
disease evolution. First diagnosis was made in 2011, which was followed by a mastectomy. 
In 2012 she was irradiated and subsequently treated with Tamoxifen. Due to poor tolerability 
of the drug and to the occurrence of bone metastasis, the patient switched endocrine therapy, 
examestane followed by fulvetrant. At the time of the first draw, she was negative for ESR1 
mutations, but a high increase in the number of CTCs was found compared to baseline CTCs 
count (80 vs. 54). The second sampling was taken only one month apart and was positive for 
the Y537S activating mutation. Furthermore, a third CTCs count was made after a further 
therapy switch to combination with palbociclib, showing a relative decrease in total number 
of CTCs (43 vs. 80), but an almost unchanged number of the ER+ population (23 vs 28). 
These prospective clinical evidences clearly indicate that the patient did not benefit from 
fulvestrant at time of ESR1 mutation detection. Instead, she benefited from the prompt 
switch to a combined therapy of palbociclib and fulvestrant, a highly effective regimen 
evaluated in the prospective, randomized, phase 3 study PALOMA-3, whose benefit appears 
irrespective of common genomic abnormalities such as ESR1 and PI3KCA [38, 39].
DISCUSSION
The frequency of ESR1 mutations in breast cancer is a matter of intense debate for the 
potential clinical utility of this information. Primary ESR1 mutations are relatively rare in 
primary tissue, up to 7% of specimens analyzed with very low allele frequencies (0.07–
0.2%), when compared to a much higher detection in patients with metastatic disease [11]. 
The first study on the detection of ESR1 mutations in patients that were exposed to 
endocrine therapy was conducted on metastatic biopsies and matched cfDNA samples [37]. 
Two hot spot mutations in codon 537 and 538 of ESR1 gene were investigated by digital 
PCR (dPCR). Those findings showed monitoring ESR1 mutations by dPCR was feasible, 
but not all mutations found in the metastatic biopsies were detected also in matched cfDNA 
[40]. In our study we used the analysis on cfDNA as a validation of the results found at the 
CTC level. All mutations found in cfDNA were confirmed in the ER+ CTCs population. In 
CTCs we detected a new mutation in codon 8 (T570I) that was not detected in cfDNA. On 
the other hand, ER expression in CTCs showed a wide heterogeneous status. Most samples 
positive for CTCs showed a mixed population (ER+ and ER-), but 5 samples positive for 
CTCs were negative for ER expression. These results suggest that analysis of both CTCs and 
cfDNA can be a useful guide in clinical practice.
Our study is the first in which the combined systems (CellSearch and DEPArray) were 
applied to assess both ER expression and all 14 ESR1 hot spot mutations by MALBAC 
single cell amplification method. The combined approach, CellSearch® and DEPArray™, 
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was tested already on cancer patients’ samples [41,42,43]. In a previous study, 510 CTCs 
were isolated from 66 MBCs. 37 CTCs were subjected to adaptor-ligation-mediated whole 
genome amplification and subsequently analyzed for the expression of the ErbB2 gene and 
for analysis of two hot spots in PIK3CA (exon 20 and 9) [41]. They demonstrated 
applicability of that workflow and also found some heterogeneity between the analyzed 
CTCs and primary tumor. Another group, studied the entire population of CTCs and white 
blood cells enriched from the CellSearch® system to genotype ESR1, PIK3CA, TP53, 
FGFR1 and FGFR2 genes, by a next generation sequencing (NGS) panel. Analysis of such 
markers also was done on cfDNA and 4 repeated samples over time during patient therapy 
monitoring. Two patients showed changes at the level of ESR1 gene mutations detected in 
cfDNA, only one in cfDNA and CTCs. This discordance can be explained by the fact that 
CTCs were analyzed as a pool with WBCs, where the predominant component is wild type 
[42]. Only recently the same group published a new study where the NGS panel was 
performed also on single CTC isolated by DEPArray™. The purpose of the study was to 
determine whether cfDNA can be compared to single CTC analysis to detect tumor mutation 
heterogeneity [44].
Our work is the first to evaluate detection of all activating ESR1 mutations among the LBD, 
at the single circulating tumor cell level in MBC patients. We also monitored the acquisition 
of endocrine resistance and validated data confirming mutations in matched cfDNA. Of the 4 
samples processed and corresponding to 3 different patients, 2 had at least one mutation that 
was confirmed also in cfDNA, but not in primary tissue. In both samples, the mutation 
detected was Y537S, positioned in exon 8 of the LBD domain of ER, as well as one of the 
most common mutations found in metastatic lesions. This mutation was present only in 
some of the CTCs from the same patient, highlighting the importance of single cell analysis 
instead of the previously pooling strategy [40,42].
The role of wild type tyrosine 537 and the effects of a number of possible amino acid 
substitutions have been thoroughly investigated [13]. This site is located in domain E, ligand 
binding and recognition region, containing the functional transcription activating domain 
ligand dipendene-2 and involved in the regulation of ER transcriptional activity. Among all 
the substitutions tested, the Y537S was the only one that showed 100% activity of the 
receptor in the absence of ligand [45]. A recent study showed that such activity can be 
partially reduced by increasing the tamoxifen or fulvestrant doses, a possible strategy to 
avoid endocrine resistance [46]. This mutation could definitely be one of the main causes of 
poor or inadequate response to hormone therapy.
Finally, we also demonstrate how our workflow allows investigation of intra-tumor 
heterogeneity. A loss of heterozygosity (LOH) was detected in one single CTC. We cannot 
totally exclude that this may be due to a technical error deriving from WGA. Analyzing a 
higher number of CTCs for each patient has in part solved this issue. For the first time, in 
our work, MALBAC has been used in combination with the CellSearch® and the 
DEPArray™ systems. Among the various techniques, any cannot ensure the absence of 
errors like false positive/negative results or allelic dropout (ADO). Several comparison 
studies have shown that each WGA technique has its own benefits and drawbacks. The main 
advantages of MALBAC are associated with reduced ADO and PCR bias, high amplification 
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efficiency even of GC rich regions and high genome coverage (up to 90%) [47]. Moreover, 
an improved ability of MALBAC in SNP variant identification has been recently reported, 
with better performance in uniformity and reproducibility [48]. Other methods, like 
SurePlex allows for a better copy number alterations (CNAs) detection, with a more 
uniformity amplification across the genome [49]. These observations led us to endorse 
MALBAC as the technique to be used in genotyping the ESR1 gene. MALBAC is therefore 
confirmed by us to be a reliable WGA method to address single CTC molecular profiling.
In conclusion, this study demonstrated the feasibility of our protocol to detect and monitor 
ESR1 gene mutations at the single CTC level in MBCs. Early detection is essential to set the 
correct treatment plan for patients, before onset of metastatic disease. In addition, analysis of 
individual CTCs could allow identification of new potentially driving mutations or even new 
genes involved in resistance. Further studies with larger numbers of patients are required to 
make this approach of use in the clinic.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Abbreviations
APC allophycocyanin
AR androgen receptor
CDH1 cadherin-1
CDK4 cyclin-dependent kinase
cfDNA circulating free DNA
CTC circulating tumor cell
DAPI (4’,6-diamidino-2-phenylindole)
EGFR2 human epidermal growth factor receptor 2
ER estrogen receptor
ERBB2 erythroblastic leukemia viral oncogene homolog 2
ESR1 estrogen receptor 1
ETV1 ets-1 variant
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FITC fluorescein-isothiocyanate
IBC inflammatory breast cancer
MALBAC multiple annealing and looping-based amplification cycles
MBC metastatic breast cancer
NCOR2 nuclear receptor corepressor 2
PE phycoerythrin
PIK3C3 phosphatidylinositol 3-kinase catalytic subunit type 3
WGA whole genome amplification
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STATEMENT OF TRANSLATIONAL RELEVANCE
Current treatment strategies including single agent endocrine agents or combinations with 
CDK4/6 inhibitors or mTOR inhibitors have increase capabilities of effective treatment 
of patients with hormone-receptor positive metastatic breast cancer. Primary or secondary 
endocrine-resistance is a major clinical challenge in the management of patients with 
advanced hormone-receptor positive breast cancer because is a dynamic phenomenon 
including development of estrogen-receptor (ESR1) mutations. The evaluation and 
longitudinal monitoring of endocrine resistance including enumeration of CTCs, 
measurement of heterogeneous estrogen-receptor expression in those cancer cells and 
detection of ESR1 mutations allows a real-time molecular monitoring allowing to adapt 
treatment modalities with potential impact on outcome.
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Figure 1. Study workflow
The total number of CTCs analyzed from 3 different patients which showed a number of ER
+ CTCs > 20. For each patient 3 WBC were recovered as negative controls. One patient was 
tested twice because of disease progression
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Figure 2. ER nuclear expression
Representative CellSearch™ images for: a) ER expression in MCF-7 cell line (event 1, 2, 3 
are ER-, event 4 and 5 are ER+); b) CTCs from patient sample (all event are ER+).
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Figure 3. DEPArray™’s imaging reports and Sanger Sequence result
a) Example of Y537S heterozygous mutation; b) The only homozygous Y537S mutation 
found in patient ID10; c) T570I novel, unreported mutation found in patient ID10.
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Table 1
Clinicopathologic features of 30 MBCs
Clinicopathologic
Features
Detail n
Age Median 56
Minimum 34
Maximum 79
Histology Ductal 18
Lobular 7
Other 2
Missing 3
Type IBC 16
No IBC 14
ER Positive 30
Negative 0
PR Positive 20
Negative 10
HER2 Positive 2
Negative 24
Missing 4
Metastasis sites n=1 11
n>1 19
ER metastatis* Positive 28
Negative 2
PR metastasis* Positive 20
Negative 10
IBC = inflammatory breast cancer;
*
ER and PR status immunohistochemistry on available metastatic lesions
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Table 2
CTCs number assessed by CellSearch® for each patient, based on ER surface expression.
Patient
ID #
CTC+/ER
−
CTC+/ER
+
Total
1 0 0 0
2* 1 3 4
3 1 4
3 0 0 0
4 0 0 0
4 1 0 1
5* 2 2 4
0 2 2
6 0 6
6 3 0 3
7* 3 0 3
2 2 4
8 0 5 5
9 2 2 4
10* 11 43 54
22 58 80
10 13 31 44
11 0 0 0
12 5 0 5
13 1 0 1
14 2 3 5
15* 9 18 27
0 1 1
16* 147 0 147
410 0 410
17 0 2 2
18* 13 15 28
5 14 19
19 19 33 52
20* 12 44 56
13 9 22
21 0 0 0
22* 1361 14 1375
931 0 931
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Patient
ID #
CTC+/ER
−
CTC+/ER
+
Total
23 0 0 0
24 0 0 0
25 22 18 40
26 19 9 28
27 0 0 0
28 0 0 0
29 0 0 0
30 0 0 0
ID = identification number;
*
more than one draw was performed during the enrollment period.
Clin Cancer Res. Author manuscript; available in PMC 2018 October 15.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Paolillo et al. Page 20
Ta
bl
e 
3
Su
m
m
ar
y 
of
 th
e 
nu
m
be
r o
f C
TC
s d
et
ec
te
d,
 is
ol
at
ed
 a
nd
 se
le
ct
ed
 to
 p
er
fo
rm
 W
G
A
Pa
tie
nt
ID
N
 C
TC
s o
n
C
el
lS
ea
rc
h®
ER
(+
,−)
N
 C
TC
s o
n
D
EP
A
rr
ay
™
ER
(+
,−)
%
 o
f C
TC
s
re
co
v
er
ed
N
 W
G
A
pe
rf
o
rm
ed
o
n
 E
R
(+
,−)
N
 W
G
A
pe
rf
o
rm
ed
 o
n
W
BC
s
19
56
(44
,12
)
17
(8,
9)
30
7(5
,2)
3
20
52
(33
,19
)
11
(6,
5)
21
5(3
,2)
3
10
*
54
(43
,11
)
15
(11
,4)
28
12
(8,
4)
3
10
*
80
(28
,52
)
19
(8,
11
)
23
16
(8,
8)
3
*
Tw
o
 d
ra
w
s 
w
er
e 
pe
rfo
rm
ed
 d
ur
in
g 
th
e 
en
ro
llm
en
t p
er
io
d;
 a
 th
ird
 c
ou
nt
 o
n 
Ce
llS
ea
rc
h®
 
w
as
 p
er
fo
rm
ed
 a
nd
 sh
ow
ed
 a
 d
ec
re
as
e 
in
 th
e 
to
ta
l n
um
be
r o
f C
TC
s (
44
), b
u
t a
n 
al
m
os
t s
ta
bl
e 
nu
m
be
r o
f E
R+
 C
TC
s 
(23
).
Clin Cancer Res. Author manuscript; available in PMC 2018 October 15.
